The continued diagnostic and prognostic application of TP53 mutations in medulloblastomas supported further genetic profiling and helped to develop the current tumor classification[8-10,32-41]: only recently, in 2016[18] and with an update in 2021[24], the World Health Organization (WHO) introduced four new diagnostic groups of this childhood brain tumor based solely on molecular genetic features [Table 2]. This evidence concerns the gene TP53 and neoplasm.